X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CT103A (equecabtagene autoleucel) is a BCMA chimeric antigen receptor autologous T cell therapy, being investigated for the treatment of Generalized Myasthenia Gravis.
Lead Product(s): Equecabtagene Autoleucel
Therapeutic Area: Immunology Product Name: CT103A
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2024
Details:
Fucaso (equecabtagene autoleucel) is a self-developed fully-human anti-BCMA, CAR T-cell injection. It is being evaluated for an expanded indication as 2nd & 3rd line treatment of relapsed and/or refractory multiple myeloma.
Lead Product(s): Equecabtagene Autoleucel
Therapeutic Area: Oncology Product Name: Fucaso
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2024
Details:
Under the collaborations, IASO Bio will receive exclusive access to the rapamycin-activated cytokine receptor platform, Umoja's synthetic cytokine receptor technology, for the development of two ex vivo iPSC-derived chimeric antigen receptor-bearing cell therapies.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Recipient: Umoja Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 03, 2024
Details:
Fucaso (equecabtagene autoleucel) is a BCMA chimeric antigen receptor autologous T cell injection, a lentiviral vector containing a CAR structure with a fully human scFv, CD8a hinger and transmembrane.
Lead Product(s): Equecabtagene Autoleucel
Therapeutic Area: Oncology Product Name: Fucaso
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Innovent Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 02, 2023
Details:
IASO-782 Injection is a fully human monoclonal antibody targeting human CD19, with Fc mutations to enhance ADCC function for treatment of autoimmune disease.
Lead Product(s): IASO-782
Therapeutic Area: Immunology Product Name: IASO-782
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2023
Details:
CT103A (equecabtagene autoleucel) is a BCMA chimeric antigen receptor autologous T cell injection, a lentiviral vector containing a CAR structure with a fully human scFv, CD8a hinger and transmembrane, 4-1BB co-stimulatory and CD3ζ activation domains.
Lead Product(s): Equecabtagene Autoleucel
Therapeutic Area: Oncology Product Name: CT103A
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2023
Details:
CT103A (equecabtagene autoleucel) is a BCMA chimeric antigen receptor autologous T cell injection, a lentiviral vector containing a CAR structure with a fully human scFv, CD8a hinger and transmembrane.
Lead Product(s): Equecabtagene Autoleucel
Therapeutic Area: Oncology Product Name: CT103A
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Shanghai Guoxin Investment & Development
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing January 17, 2023
Details:
CT103A (equecabtagene autoleucel), a CAR T-Cell Therapy targeting the B-cell maturation antigen, contains a fully human single-chain variable fragment, allowing it to bypass potential anti-CAR immunogenicity of the host while retaining anti-tumor activity.
Lead Product(s): Equecabtagene Autoleucel
Therapeutic Area: Oncology Product Name: CT103A
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
Details:
The collaboration will focus on bringing off-the-shelf therapies to patients with hematological malignancies, initially acute myeloid leukemia (AML), with a goal of increasing patient accessibility.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Recipient: Umoja Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 21, 2022
Details:
IASO Bio has the right of first negotiation to develop and commercialize Cabaletta’s products including CABA-201, using the licensed sequence in the Greater China region.
Lead Product(s): CABA-201
Therapeutic Area: Immunology Product Name: CABA-201
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cabaletta Bio
Deal Size: $162.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 11, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
